nodes	percent_of_prediction	percent_of_DWPC	metapath
Lisinopril—ABCB1—esophageal cancer	0.654	1	CbGaD
Lisinopril—ACE—thoracic aorta—esophageal cancer	0.0586	0.533	CbGeAlD
Lisinopril—ACE2—digestive system—esophageal cancer	0.00819	0.0744	CbGeAlD
Lisinopril—ACE2—lung—esophageal cancer	0.00684	0.0621	CbGeAlD
Lisinopril—ACE—neck—esophageal cancer	0.00517	0.047	CbGeAlD
Lisinopril—SLC15A1—epithelium—esophageal cancer	0.00491	0.0446	CbGeAlD
Lisinopril—ACE2—lymph node—esophageal cancer	0.00468	0.0425	CbGeAlD
Lisinopril—SLC15A1—digestive system—esophageal cancer	0.00373	0.0339	CbGeAlD
Lisinopril—ACE—epithelium—esophageal cancer	0.00352	0.032	CbGeAlD
Lisinopril—ACE—smooth muscle tissue—esophageal cancer	0.00339	0.0308	CbGeAlD
Lisinopril—ACE—digestive system—esophageal cancer	0.00268	0.0243	CbGeAlD
Lisinopril—ACE—lung—esophageal cancer	0.00224	0.0203	CbGeAlD
Lisinopril—ACE—lymph node—esophageal cancer	0.00153	0.0139	CbGeAlD
Lisinopril—ABCB1—epithelium—esophageal cancer	0.00124	0.0113	CbGeAlD
Lisinopril—ABCB1—trachea—esophageal cancer	0.0011	0.00995	CbGeAlD
Lisinopril—ABCB1—digestive system—esophageal cancer	0.000942	0.00856	CbGeAlD
Lisinopril—ABCB1—lung—esophageal cancer	0.000787	0.00715	CbGeAlD
Lisinopril—Face oedema—Capecitabine—esophageal cancer	0.000681	0.00295	CcSEcCtD
Lisinopril—Bradycardia—Cisplatin—esophageal cancer	0.000674	0.00292	CcSEcCtD
Lisinopril—Irritability—Capecitabine—esophageal cancer	0.000674	0.00292	CcSEcCtD
Lisinopril—Cardiac arrest—Capecitabine—esophageal cancer	0.000671	0.0029	CcSEcCtD
Lisinopril—Ataxia—Capecitabine—esophageal cancer	0.000664	0.00287	CcSEcCtD
Lisinopril—Blood creatinine increased—Capecitabine—esophageal cancer	0.000661	0.00286	CcSEcCtD
Lisinopril—Dehydration—Capecitabine—esophageal cancer	0.000656	0.00284	CcSEcCtD
Lisinopril—Bladder pain—Methotrexate—esophageal cancer	0.000654	0.00283	CcSEcCtD
Lisinopril—Urinary tract disorder—Cisplatin—esophageal cancer	0.000654	0.00283	CcSEcCtD
Lisinopril—Urethral disorder—Cisplatin—esophageal cancer	0.000649	0.00281	CcSEcCtD
Lisinopril—Orthostatic hypotension—Capecitabine—esophageal cancer	0.000645	0.00279	CcSEcCtD
Lisinopril—Pulmonary oedema—Methotrexate—esophageal cancer	0.000644	0.00279	CcSEcCtD
Lisinopril—Breast disorder—Capecitabine—esophageal cancer	0.000638	0.00276	CcSEcCtD
Lisinopril—Toxic epidermal necrolysis—Capecitabine—esophageal cancer	0.000636	0.00275	CcSEcCtD
Lisinopril—Nasopharyngitis—Capecitabine—esophageal cancer	0.000631	0.00273	CcSEcCtD
Lisinopril—Gastritis—Capecitabine—esophageal cancer	0.000625	0.0027	CcSEcCtD
Lisinopril—Tinnitus—Cisplatin—esophageal cancer	0.000618	0.00267	CcSEcCtD
Lisinopril—Flushing—Cisplatin—esophageal cancer	0.000615	0.00266	CcSEcCtD
Lisinopril—Asthma—Capecitabine—esophageal cancer	0.00061	0.00264	CcSEcCtD
Lisinopril—Influenza—Capecitabine—esophageal cancer	0.00061	0.00264	CcSEcCtD
Lisinopril—Diabetes mellitus—Methotrexate—esophageal cancer	0.000604	0.00261	CcSEcCtD
Lisinopril—Bronchospasm—Capecitabine—esophageal cancer	0.0006	0.0026	CcSEcCtD
Lisinopril—Photosensitivity—Methotrexate—esophageal cancer	0.000598	0.00259	CcSEcCtD
Lisinopril—Mediastinal disorder—Cisplatin—esophageal cancer	0.000597	0.00258	CcSEcCtD
Lisinopril—Sweating increased—Capecitabine—esophageal cancer	0.000594	0.00257	CcSEcCtD
Lisinopril—Angina pectoris—Capecitabine—esophageal cancer	0.000594	0.00257	CcSEcCtD
Lisinopril—Arrhythmia—Cisplatin—esophageal cancer	0.000592	0.00256	CcSEcCtD
Lisinopril—Bronchitis—Capecitabine—esophageal cancer	0.000587	0.00254	CcSEcCtD
Lisinopril—Alopecia—Cisplatin—esophageal cancer	0.000585	0.00253	CcSEcCtD
Lisinopril—Hepatic failure—Methotrexate—esophageal cancer	0.000585	0.00253	CcSEcCtD
Lisinopril—Pancytopenia—Capecitabine—esophageal cancer	0.000579	0.00251	CcSEcCtD
Lisinopril—Erythema—Cisplatin—esophageal cancer	0.000577	0.0025	CcSEcCtD
Lisinopril—Malnutrition—Cisplatin—esophageal cancer	0.000577	0.0025	CcSEcCtD
Lisinopril—Dysuria—Capecitabine—esophageal cancer	0.00057	0.00247	CcSEcCtD
Lisinopril—Neutropenia—Capecitabine—esophageal cancer	0.00057	0.00247	CcSEcCtD
Lisinopril—Renal failure acute—Methotrexate—esophageal cancer	0.000569	0.00246	CcSEcCtD
Lisinopril—Flatulence—Cisplatin—esophageal cancer	0.000568	0.00246	CcSEcCtD
Lisinopril—Upper respiratory tract infection—Capecitabine—esophageal cancer	0.000567	0.00245	CcSEcCtD
Lisinopril—Photosensitivity reaction—Capecitabine—esophageal cancer	0.000557	0.00241	CcSEcCtD
Lisinopril—Weight increased—Capecitabine—esophageal cancer	0.000555	0.0024	CcSEcCtD
Lisinopril—Muscle spasms—Cisplatin—esophageal cancer	0.000554	0.0024	CcSEcCtD
Lisinopril—Weight decreased—Capecitabine—esophageal cancer	0.000552	0.00239	CcSEcCtD
Lisinopril—Hyperglycaemia—Capecitabine—esophageal cancer	0.00055	0.00238	CcSEcCtD
Lisinopril—Pneumonia—Capecitabine—esophageal cancer	0.000547	0.00237	CcSEcCtD
Lisinopril—Vision blurred—Cisplatin—esophageal cancer	0.000543	0.00235	CcSEcCtD
Lisinopril—Anaphylactoid reaction—Methotrexate—esophageal cancer	0.000543	0.00235	CcSEcCtD
Lisinopril—Depression—Capecitabine—esophageal cancer	0.000542	0.00235	CcSEcCtD
Lisinopril—Tremor—Cisplatin—esophageal cancer	0.00054	0.00234	CcSEcCtD
Lisinopril—Stevens-Johnson syndrome—Capecitabine—esophageal cancer	0.000539	0.00233	CcSEcCtD
Lisinopril—ABCB1—lymph node—esophageal cancer	0.000538	0.00489	CbGeAlD
Lisinopril—Acute coronary syndrome—Capecitabine—esophageal cancer	0.000536	0.00232	CcSEcCtD
Lisinopril—Cerebrovascular accident—Methotrexate—esophageal cancer	0.000536	0.00232	CcSEcCtD
Lisinopril—Ill-defined disorder—Cisplatin—esophageal cancer	0.000535	0.00232	CcSEcCtD
Lisinopril—Renal failure—Capecitabine—esophageal cancer	0.000535	0.00231	CcSEcCtD
Lisinopril—Myocardial infarction—Capecitabine—esophageal cancer	0.000533	0.00231	CcSEcCtD
Lisinopril—Neuropathy peripheral—Capecitabine—esophageal cancer	0.000533	0.00231	CcSEcCtD
Lisinopril—Anaemia—Cisplatin—esophageal cancer	0.000533	0.00231	CcSEcCtD
Lisinopril—Jaundice—Capecitabine—esophageal cancer	0.00053	0.00229	CcSEcCtD
Lisinopril—Urinary tract infection—Capecitabine—esophageal cancer	0.000529	0.00229	CcSEcCtD
Lisinopril—Osteoarthritis—Methotrexate—esophageal cancer	0.000525	0.00227	CcSEcCtD
Lisinopril—Malaise—Cisplatin—esophageal cancer	0.00052	0.00225	CcSEcCtD
Lisinopril—Haematuria—Capecitabine—esophageal cancer	0.000519	0.00224	CcSEcCtD
Lisinopril—Leukopenia—Cisplatin—esophageal cancer	0.000516	0.00223	CcSEcCtD
Lisinopril—Hepatobiliary disease—Capecitabine—esophageal cancer	0.000514	0.00223	CcSEcCtD
Lisinopril—Epistaxis—Capecitabine—esophageal cancer	0.000513	0.00222	CcSEcCtD
Lisinopril—Agranulocytosis—Capecitabine—esophageal cancer	0.000508	0.0022	CcSEcCtD
Lisinopril—ACE2—Peptide hormone metabolism—SLC30A7—esophageal cancer	0.000503	0.116	CbGpPWpGaD
Lisinopril—Irritability—Methotrexate—esophageal cancer	0.000502	0.00217	CcSEcCtD
Lisinopril—Bradycardia—Capecitabine—esophageal cancer	0.000497	0.00215	CcSEcCtD
Lisinopril—Ataxia—Methotrexate—esophageal cancer	0.000494	0.00214	CcSEcCtD
Lisinopril—Myalgia—Cisplatin—esophageal cancer	0.000491	0.00212	CcSEcCtD
Lisinopril—Rhinitis—Capecitabine—esophageal cancer	0.00049	0.00212	CcSEcCtD
Lisinopril—Anxiety—Cisplatin—esophageal cancer	0.000489	0.00212	CcSEcCtD
Lisinopril—Hepatitis—Capecitabine—esophageal cancer	0.000488	0.00211	CcSEcCtD
Lisinopril—Unspecified disorder of skin and subcutaneous tissue—Cisplatin—esophageal cancer	0.000488	0.00211	CcSEcCtD
Lisinopril—Discomfort—Cisplatin—esophageal cancer	0.000485	0.0021	CcSEcCtD
Lisinopril—Pharyngitis—Capecitabine—esophageal cancer	0.000485	0.0021	CcSEcCtD
Lisinopril—Urinary tract disorder—Capecitabine—esophageal cancer	0.000482	0.00209	CcSEcCtD
Lisinopril—Oedema peripheral—Capecitabine—esophageal cancer	0.000481	0.00208	CcSEcCtD
Lisinopril—Urethral disorder—Capecitabine—esophageal cancer	0.000479	0.00207	CcSEcCtD
Lisinopril—Breast disorder—Methotrexate—esophageal cancer	0.000475	0.00205	CcSEcCtD
Lisinopril—Toxic epidermal necrolysis—Methotrexate—esophageal cancer	0.000473	0.00205	CcSEcCtD
Lisinopril—Anaphylactic shock—Cisplatin—esophageal cancer	0.000471	0.00204	CcSEcCtD
Lisinopril—Oedema—Cisplatin—esophageal cancer	0.000471	0.00204	CcSEcCtD
Lisinopril—Infection—Cisplatin—esophageal cancer	0.000468	0.00202	CcSEcCtD
Lisinopril—Erythema multiforme—Capecitabine—esophageal cancer	0.000462	0.002	CcSEcCtD
Lisinopril—Thrombocytopenia—Cisplatin—esophageal cancer	0.000461	0.00199	CcSEcCtD
Lisinopril—Tachycardia—Cisplatin—esophageal cancer	0.000459	0.00199	CcSEcCtD
Lisinopril—Skin disorder—Cisplatin—esophageal cancer	0.000457	0.00198	CcSEcCtD
Lisinopril—Tinnitus—Capecitabine—esophageal cancer	0.000455	0.00197	CcSEcCtD
Lisinopril—Hyperhidrosis—Cisplatin—esophageal cancer	0.000455	0.00197	CcSEcCtD
Lisinopril—Asthma—Methotrexate—esophageal cancer	0.000454	0.00197	CcSEcCtD
Lisinopril—Flushing—Capecitabine—esophageal cancer	0.000453	0.00196	CcSEcCtD
Lisinopril—Eosinophilia—Methotrexate—esophageal cancer	0.00045	0.00195	CcSEcCtD
Lisinopril—Anorexia—Cisplatin—esophageal cancer	0.000449	0.00194	CcSEcCtD
Lisinopril—Pancreatitis—Methotrexate—esophageal cancer	0.000445	0.00193	CcSEcCtD
Lisinopril—Angiopathy—Capecitabine—esophageal cancer	0.000443	0.00192	CcSEcCtD
Lisinopril—Mediastinal disorder—Capecitabine—esophageal cancer	0.00044	0.0019	CcSEcCtD
Lisinopril—Hypotension—Cisplatin—esophageal cancer	0.00044	0.0019	CcSEcCtD
Lisinopril—ACE2—ACE Inhibitor Pathway—NOS3—esophageal cancer	0.000439	0.102	CbGpPWpGaD
Lisinopril—Chills—Capecitabine—esophageal cancer	0.000438	0.0019	CcSEcCtD
Lisinopril—Arrhythmia—Capecitabine—esophageal cancer	0.000436	0.00189	CcSEcCtD
Lisinopril—Alopecia—Capecitabine—esophageal cancer	0.000432	0.00187	CcSEcCtD
Lisinopril—Pancytopenia—Methotrexate—esophageal cancer	0.000431	0.00187	CcSEcCtD
Lisinopril—Musculoskeletal discomfort—Cisplatin—esophageal cancer	0.000429	0.00186	CcSEcCtD
Lisinopril—Mental disorder—Capecitabine—esophageal cancer	0.000428	0.00185	CcSEcCtD
Lisinopril—Malnutrition—Capecitabine—esophageal cancer	0.000425	0.00184	CcSEcCtD
Lisinopril—Erythema—Capecitabine—esophageal cancer	0.000425	0.00184	CcSEcCtD
Lisinopril—Dysuria—Methotrexate—esophageal cancer	0.000425	0.00184	CcSEcCtD
Lisinopril—Neutropenia—Methotrexate—esophageal cancer	0.000425	0.00184	CcSEcCtD
Lisinopril—Paraesthesia—Cisplatin—esophageal cancer	0.000423	0.00183	CcSEcCtD
Lisinopril—Upper respiratory tract infection—Methotrexate—esophageal cancer	0.000422	0.00183	CcSEcCtD
Lisinopril—Dyspnoea—Cisplatin—esophageal cancer	0.00042	0.00182	CcSEcCtD
Lisinopril—Flatulence—Capecitabine—esophageal cancer	0.000419	0.00181	CcSEcCtD
Lisinopril—Erectile dysfunction—Methotrexate—esophageal cancer	0.000418	0.00181	CcSEcCtD
Lisinopril—Dysgeusia—Capecitabine—esophageal cancer	0.000416	0.0018	CcSEcCtD
Lisinopril—Photosensitivity reaction—Methotrexate—esophageal cancer	0.000415	0.00179	CcSEcCtD
Lisinopril—Back pain—Capecitabine—esophageal cancer	0.000411	0.00178	CcSEcCtD
Lisinopril—Decreased appetite—Cisplatin—esophageal cancer	0.000409	0.00177	CcSEcCtD
Lisinopril—Muscle spasms—Capecitabine—esophageal cancer	0.000409	0.00177	CcSEcCtD
Lisinopril—Pneumonia—Methotrexate—esophageal cancer	0.000407	0.00176	CcSEcCtD
Lisinopril—Gastrointestinal disorder—Cisplatin—esophageal cancer	0.000406	0.00176	CcSEcCtD
Lisinopril—Depression—Methotrexate—esophageal cancer	0.000404	0.00175	CcSEcCtD
Lisinopril—Pain—Cisplatin—esophageal cancer	0.000402	0.00174	CcSEcCtD
Lisinopril—Stevens-Johnson syndrome—Methotrexate—esophageal cancer	0.000401	0.00174	CcSEcCtD
Lisinopril—Vision blurred—Capecitabine—esophageal cancer	0.000401	0.00173	CcSEcCtD
Lisinopril—Tremor—Capecitabine—esophageal cancer	0.000398	0.00172	CcSEcCtD
Lisinopril—Renal failure—Methotrexate—esophageal cancer	0.000398	0.00172	CcSEcCtD
Lisinopril—Ill-defined disorder—Capecitabine—esophageal cancer	0.000394	0.00171	CcSEcCtD
Lisinopril—Anaemia—Capecitabine—esophageal cancer	0.000393	0.0017	CcSEcCtD
Lisinopril—Sweating—Methotrexate—esophageal cancer	0.000388	0.00168	CcSEcCtD
Lisinopril—Feeling abnormal—Cisplatin—esophageal cancer	0.000388	0.00168	CcSEcCtD
Lisinopril—Haematuria—Methotrexate—esophageal cancer	0.000386	0.00167	CcSEcCtD
Lisinopril—Malaise—Capecitabine—esophageal cancer	0.000383	0.00166	CcSEcCtD
Lisinopril—Hepatobiliary disease—Methotrexate—esophageal cancer	0.000383	0.00166	CcSEcCtD
Lisinopril—Epistaxis—Methotrexate—esophageal cancer	0.000382	0.00165	CcSEcCtD
Lisinopril—Vertigo—Capecitabine—esophageal cancer	0.000382	0.00165	CcSEcCtD
Lisinopril—Syncope—Capecitabine—esophageal cancer	0.000381	0.00165	CcSEcCtD
Lisinopril—Leukopenia—Capecitabine—esophageal cancer	0.000381	0.00165	CcSEcCtD
Lisinopril—Agranulocytosis—Methotrexate—esophageal cancer	0.000378	0.00164	CcSEcCtD
Lisinopril—Palpitations—Capecitabine—esophageal cancer	0.000376	0.00163	CcSEcCtD
Lisinopril—Loss of consciousness—Capecitabine—esophageal cancer	0.000374	0.00162	CcSEcCtD
Lisinopril—Body temperature increased—Cisplatin—esophageal cancer	0.000372	0.00161	CcSEcCtD
Lisinopril—Cough—Capecitabine—esophageal cancer	0.000371	0.00161	CcSEcCtD
Lisinopril—Hepatitis—Methotrexate—esophageal cancer	0.000364	0.00157	CcSEcCtD
Lisinopril—Arthralgia—Capecitabine—esophageal cancer	0.000362	0.00157	CcSEcCtD
Lisinopril—Chest pain—Capecitabine—esophageal cancer	0.000362	0.00157	CcSEcCtD
Lisinopril—Myalgia—Capecitabine—esophageal cancer	0.000362	0.00157	CcSEcCtD
Lisinopril—Pharyngitis—Methotrexate—esophageal cancer	0.000361	0.00156	CcSEcCtD
Lisinopril—Anxiety—Capecitabine—esophageal cancer	0.000361	0.00156	CcSEcCtD
Lisinopril—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—esophageal cancer	0.000359	0.00156	CcSEcCtD
Lisinopril—Urinary tract disorder—Methotrexate—esophageal cancer	0.000359	0.00155	CcSEcCtD
Lisinopril—Discomfort—Capecitabine—esophageal cancer	0.000358	0.00155	CcSEcCtD
Lisinopril—Urethral disorder—Methotrexate—esophageal cancer	0.000356	0.00154	CcSEcCtD
Lisinopril—Dry mouth—Capecitabine—esophageal cancer	0.000354	0.00153	CcSEcCtD
Lisinopril—Confusional state—Capecitabine—esophageal cancer	0.00035	0.00151	CcSEcCtD
Lisinopril—Oedema—Capecitabine—esophageal cancer	0.000347	0.0015	CcSEcCtD
Lisinopril—Hypersensitivity—Cisplatin—esophageal cancer	0.000347	0.0015	CcSEcCtD
Lisinopril—Infection—Capecitabine—esophageal cancer	0.000345	0.00149	CcSEcCtD
Lisinopril—Erythema multiforme—Methotrexate—esophageal cancer	0.000344	0.00149	CcSEcCtD
Lisinopril—Shock—Capecitabine—esophageal cancer	0.000341	0.00148	CcSEcCtD
Lisinopril—Thrombocytopenia—Capecitabine—esophageal cancer	0.00034	0.00147	CcSEcCtD
Lisinopril—Tinnitus—Methotrexate—esophageal cancer	0.000339	0.00147	CcSEcCtD
Lisinopril—Tachycardia—Capecitabine—esophageal cancer	0.000339	0.00147	CcSEcCtD
Lisinopril—Asthenia—Cisplatin—esophageal cancer	0.000338	0.00146	CcSEcCtD
Lisinopril—Skin disorder—Capecitabine—esophageal cancer	0.000337	0.00146	CcSEcCtD
Lisinopril—Hyperhidrosis—Capecitabine—esophageal cancer	0.000335	0.00145	CcSEcCtD
Lisinopril—Anorexia—Capecitabine—esophageal cancer	0.000331	0.00143	CcSEcCtD
Lisinopril—Angiopathy—Methotrexate—esophageal cancer	0.00033	0.00143	CcSEcCtD
Lisinopril—Mediastinal disorder—Methotrexate—esophageal cancer	0.000328	0.00142	CcSEcCtD
Lisinopril—Chills—Methotrexate—esophageal cancer	0.000326	0.00141	CcSEcCtD
Lisinopril—Hypotension—Capecitabine—esophageal cancer	0.000324	0.0014	CcSEcCtD
Lisinopril—Diarrhoea—Cisplatin—esophageal cancer	0.000322	0.00139	CcSEcCtD
Lisinopril—Alopecia—Methotrexate—esophageal cancer	0.000321	0.00139	CcSEcCtD
Lisinopril—Mental disorder—Methotrexate—esophageal cancer	0.000318	0.00138	CcSEcCtD
Lisinopril—Erythema—Methotrexate—esophageal cancer	0.000316	0.00137	CcSEcCtD
Lisinopril—Malnutrition—Methotrexate—esophageal cancer	0.000316	0.00137	CcSEcCtD
Lisinopril—Musculoskeletal discomfort—Capecitabine—esophageal cancer	0.000316	0.00137	CcSEcCtD
Lisinopril—Insomnia—Capecitabine—esophageal cancer	0.000314	0.00136	CcSEcCtD
Lisinopril—Paraesthesia—Capecitabine—esophageal cancer	0.000312	0.00135	CcSEcCtD
Lisinopril—Dysgeusia—Methotrexate—esophageal cancer	0.00031	0.00134	CcSEcCtD
Lisinopril—Dyspnoea—Capecitabine—esophageal cancer	0.000309	0.00134	CcSEcCtD
Lisinopril—Back pain—Methotrexate—esophageal cancer	0.000306	0.00132	CcSEcCtD
Lisinopril—Dyspepsia—Capecitabine—esophageal cancer	0.000305	0.00132	CcSEcCtD
Lisinopril—Decreased appetite—Capecitabine—esophageal cancer	0.000302	0.0013	CcSEcCtD
Lisinopril—Gastrointestinal disorder—Capecitabine—esophageal cancer	0.0003	0.0013	CcSEcCtD
Lisinopril—Vomiting—Cisplatin—esophageal cancer	0.000299	0.00129	CcSEcCtD
Lisinopril—Fatigue—Capecitabine—esophageal cancer	0.000299	0.00129	CcSEcCtD
Lisinopril—Vision blurred—Methotrexate—esophageal cancer	0.000298	0.00129	CcSEcCtD
Lisinopril—Rash—Cisplatin—esophageal cancer	0.000297	0.00128	CcSEcCtD
Lisinopril—Pain—Capecitabine—esophageal cancer	0.000297	0.00128	CcSEcCtD
Lisinopril—Constipation—Capecitabine—esophageal cancer	0.000297	0.00128	CcSEcCtD
Lisinopril—Dermatitis—Cisplatin—esophageal cancer	0.000296	0.00128	CcSEcCtD
Lisinopril—Ill-defined disorder—Methotrexate—esophageal cancer	0.000294	0.00127	CcSEcCtD
Lisinopril—Anaemia—Methotrexate—esophageal cancer	0.000292	0.00127	CcSEcCtD
Lisinopril—Feeling abnormal—Capecitabine—esophageal cancer	0.000286	0.00124	CcSEcCtD
Lisinopril—Malaise—Methotrexate—esophageal cancer	0.000285	0.00123	CcSEcCtD
Lisinopril—Vertigo—Methotrexate—esophageal cancer	0.000284	0.00123	CcSEcCtD
Lisinopril—Gastrointestinal pain—Capecitabine—esophageal cancer	0.000284	0.00123	CcSEcCtD
Lisinopril—Leukopenia—Methotrexate—esophageal cancer	0.000283	0.00123	CcSEcCtD
Lisinopril—Nausea—Cisplatin—esophageal cancer	0.00028	0.00121	CcSEcCtD
Lisinopril—Cough—Methotrexate—esophageal cancer	0.000276	0.00119	CcSEcCtD
Lisinopril—Urticaria—Capecitabine—esophageal cancer	0.000276	0.00119	CcSEcCtD
Lisinopril—Body temperature increased—Capecitabine—esophageal cancer	0.000274	0.00119	CcSEcCtD
Lisinopril—Abdominal pain—Capecitabine—esophageal cancer	0.000274	0.00119	CcSEcCtD
Lisinopril—Nateglinide—PTGS1—esophageal cancer	0.000274	0.373	CrCbGaD
Lisinopril—Myalgia—Methotrexate—esophageal cancer	0.000269	0.00117	CcSEcCtD
Lisinopril—Chest pain—Methotrexate—esophageal cancer	0.000269	0.00117	CcSEcCtD
Lisinopril—Arthralgia—Methotrexate—esophageal cancer	0.000269	0.00117	CcSEcCtD
Lisinopril—ACE2—Peptide hormone metabolism—GHRL—esophageal cancer	0.000269	0.0622	CbGpPWpGaD
Lisinopril—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—esophageal cancer	0.000268	0.00116	CcSEcCtD
Lisinopril—Discomfort—Methotrexate—esophageal cancer	0.000266	0.00115	CcSEcCtD
Lisinopril—Cilazapril—ABCB1—esophageal cancer	0.000265	0.362	CrCbGaD
Lisinopril—Confusional state—Methotrexate—esophageal cancer	0.00026	0.00113	CcSEcCtD
Lisinopril—Anaphylactic shock—Methotrexate—esophageal cancer	0.000258	0.00112	CcSEcCtD
Lisinopril—Infection—Methotrexate—esophageal cancer	0.000257	0.00111	CcSEcCtD
Lisinopril—Hypersensitivity—Capecitabine—esophageal cancer	0.000256	0.00111	CcSEcCtD
Lisinopril—Thrombocytopenia—Methotrexate—esophageal cancer	0.000253	0.00109	CcSEcCtD
Lisinopril—Skin disorder—Methotrexate—esophageal cancer	0.000251	0.00109	CcSEcCtD
Lisinopril—Hyperhidrosis—Methotrexate—esophageal cancer	0.00025	0.00108	CcSEcCtD
Lisinopril—Asthenia—Capecitabine—esophageal cancer	0.000249	0.00108	CcSEcCtD
Lisinopril—Anorexia—Methotrexate—esophageal cancer	0.000246	0.00107	CcSEcCtD
Lisinopril—Pruritus—Capecitabine—esophageal cancer	0.000245	0.00106	CcSEcCtD
Lisinopril—Hypotension—Methotrexate—esophageal cancer	0.000241	0.00104	CcSEcCtD
Lisinopril—Diarrhoea—Capecitabine—esophageal cancer	0.000237	0.00103	CcSEcCtD
Lisinopril—Musculoskeletal discomfort—Methotrexate—esophageal cancer	0.000235	0.00102	CcSEcCtD
Lisinopril—Insomnia—Methotrexate—esophageal cancer	0.000234	0.00101	CcSEcCtD
Lisinopril—Paraesthesia—Methotrexate—esophageal cancer	0.000232	0.001	CcSEcCtD
Lisinopril—Dyspnoea—Methotrexate—esophageal cancer	0.00023	0.000996	CcSEcCtD
Lisinopril—Somnolence—Methotrexate—esophageal cancer	0.00023	0.000993	CcSEcCtD
Lisinopril—Dizziness—Capecitabine—esophageal cancer	0.000229	0.000993	CcSEcCtD
Lisinopril—Dyspepsia—Methotrexate—esophageal cancer	0.000227	0.000984	CcSEcCtD
Lisinopril—ACE—Peptide hormone metabolism—SLC30A7—esophageal cancer	0.000225	0.052	CbGpPWpGaD
Lisinopril—Decreased appetite—Methotrexate—esophageal cancer	0.000225	0.000971	CcSEcCtD
Lisinopril—Gastrointestinal disorder—Methotrexate—esophageal cancer	0.000223	0.000965	CcSEcCtD
Lisinopril—Fatigue—Methotrexate—esophageal cancer	0.000223	0.000963	CcSEcCtD
Lisinopril—Pain—Methotrexate—esophageal cancer	0.000221	0.000956	CcSEcCtD
Lisinopril—ABCB1—Codeine and Morphine Metabolism—ABCC2—esophageal cancer	0.000221	0.0511	CbGpPWpGaD
Lisinopril—Vomiting—Capecitabine—esophageal cancer	0.000221	0.000954	CcSEcCtD
Lisinopril—Rash—Capecitabine—esophageal cancer	0.000219	0.000946	CcSEcCtD
Lisinopril—Dermatitis—Capecitabine—esophageal cancer	0.000219	0.000946	CcSEcCtD
Lisinopril—Headache—Capecitabine—esophageal cancer	0.000217	0.00094	CcSEcCtD
Lisinopril—Feeling abnormal—Methotrexate—esophageal cancer	0.000213	0.000921	CcSEcCtD
Lisinopril—Gastrointestinal pain—Methotrexate—esophageal cancer	0.000211	0.000914	CcSEcCtD
Lisinopril—Nausea—Capecitabine—esophageal cancer	0.000206	0.000892	CcSEcCtD
Lisinopril—Urticaria—Methotrexate—esophageal cancer	0.000205	0.000888	CcSEcCtD
Lisinopril—Abdominal pain—Methotrexate—esophageal cancer	0.000204	0.000883	CcSEcCtD
Lisinopril—Body temperature increased—Methotrexate—esophageal cancer	0.000204	0.000883	CcSEcCtD
Lisinopril—ACE—ACE Inhibitor Pathway—NOS3—esophageal cancer	0.000196	0.0454	CbGpPWpGaD
Lisinopril—Enalapril—ABCB1—esophageal cancer	0.000195	0.266	CrCbGaD
Lisinopril—Hypersensitivity—Methotrexate—esophageal cancer	0.00019	0.000823	CcSEcCtD
Lisinopril—Asthenia—Methotrexate—esophageal cancer	0.000185	0.000802	CcSEcCtD
Lisinopril—Pruritus—Methotrexate—esophageal cancer	0.000183	0.000791	CcSEcCtD
Lisinopril—Diarrhoea—Methotrexate—esophageal cancer	0.000177	0.000765	CcSEcCtD
Lisinopril—Dizziness—Methotrexate—esophageal cancer	0.000171	0.000739	CcSEcCtD
Lisinopril—Vomiting—Methotrexate—esophageal cancer	0.000164	0.000711	CcSEcCtD
Lisinopril—Rash—Methotrexate—esophageal cancer	0.000163	0.000705	CcSEcCtD
Lisinopril—Dermatitis—Methotrexate—esophageal cancer	0.000163	0.000704	CcSEcCtD
Lisinopril—Headache—Methotrexate—esophageal cancer	0.000162	0.0007	CcSEcCtD
Lisinopril—Nausea—Methotrexate—esophageal cancer	0.000153	0.000664	CcSEcCtD
Lisinopril—ABCB1—Drug Induction of Bile Acid Pathway—NR1I2—esophageal cancer	0.000136	0.0314	CbGpPWpGaD
Lisinopril—ABCB1—Drug Induction of Bile Acid Pathway—ABCC2—esophageal cancer	0.000121	0.028	CbGpPWpGaD
Lisinopril—ACE—Peptide hormone metabolism—GHRL—esophageal cancer	0.00012	0.0278	CbGpPWpGaD
Lisinopril—ACE2—Metabolism of proteins—XBP1—esophageal cancer	9.9e-05	0.0229	CbGpPWpGaD
Lisinopril—ACE2—Metabolism of proteins—SLC30A7—esophageal cancer	9.5e-05	0.022	CbGpPWpGaD
Lisinopril—ACE2—Metabolism of proteins—ST6GAL1—esophageal cancer	8.55e-05	0.0198	CbGpPWpGaD
Lisinopril—ABCB1—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP26A1—esophageal cancer	7.78e-05	0.018	CbGpPWpGaD
Lisinopril—ABCB1—Nuclear Receptors in Lipid Metabolism and Toxicity—NR1I2—esophageal cancer	7.78e-05	0.018	CbGpPWpGaD
Lisinopril—ABCB1—Constitutive Androstane Receptor Pathway—ABCC2—esophageal cancer	7.28e-05	0.0169	CbGpPWpGaD
Lisinopril—ABCB1—Nuclear Receptors in Lipid Metabolism and Toxicity—ABCC2—esophageal cancer	6.94e-05	0.0161	CbGpPWpGaD
Lisinopril—ABCB1—ABC-family proteins mediated transport—ABCC2—esophageal cancer	6.63e-05	0.0154	CbGpPWpGaD
Lisinopril—ACE2—Metabolism of proteins—ACTB—esophageal cancer	5.89e-05	0.0136	CbGpPWpGaD
Lisinopril—ABCB1—Constitutive Androstane Receptor Pathway—CYP2A6—esophageal cancer	5.82e-05	0.0135	CbGpPWpGaD
Lisinopril—SLC15A1—SLC-mediated transmembrane transport—SLC39A6—esophageal cancer	5.82e-05	0.0135	CbGpPWpGaD
Lisinopril—ACE2—Metabolism of proteins—HSPA5—esophageal cancer	5.32e-05	0.0123	CbGpPWpGaD
Lisinopril—SLC15A1—SLC-mediated transmembrane transport—SLC30A7—esophageal cancer	5.32e-05	0.0123	CbGpPWpGaD
Lisinopril—ACE2—Metabolism of proteins—CALR—esophageal cancer	5.16e-05	0.0119	CbGpPWpGaD
Lisinopril—ACE2—Metabolism of proteins—GHRL—esophageal cancer	5.07e-05	0.0117	CbGpPWpGaD
Lisinopril—ACE2—Metabolism of proteins—FBXW7—esophageal cancer	4.99e-05	0.0116	CbGpPWpGaD
Lisinopril—ACE—Metabolism of proteins—XBP1—esophageal cancer	4.42e-05	0.0102	CbGpPWpGaD
Lisinopril—ACE—Metabolism of proteins—SLC30A7—esophageal cancer	4.24e-05	0.00982	CbGpPWpGaD
Lisinopril—ACE—Metabolism of proteins—ST6GAL1—esophageal cancer	3.82e-05	0.00884	CbGpPWpGaD
Lisinopril—SLC15A1—Transmembrane transport of small molecules—SLC10A2—esophageal cancer	3.32e-05	0.00768	CbGpPWpGaD
Lisinopril—SLC15A1—Transmembrane transport of small molecules—ATP1B2—esophageal cancer	3.12e-05	0.00722	CbGpPWpGaD
Lisinopril—ABCB1—HIF-1-alpha transcription factor network—ENO1—esophageal cancer	3.09e-05	0.00716	CbGpPWpGaD
Lisinopril—SLC15A1—Transmembrane transport of small molecules—SLC39A6—esophageal cancer	2.96e-05	0.00684	CbGpPWpGaD
Lisinopril—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—ABL1—esophageal cancer	2.84e-05	0.00657	CbGpPWpGaD
Lisinopril—SLC15A1—Transmembrane transport of small molecules—AQP3—esophageal cancer	2.82e-05	0.00653	CbGpPWpGaD
Lisinopril—SLC15A1—Transmembrane transport of small molecules—ATP4A—esophageal cancer	2.7e-05	0.00626	CbGpPWpGaD
Lisinopril—SLC15A1—Transmembrane transport of small molecules—SLC30A7—esophageal cancer	2.7e-05	0.00626	CbGpPWpGaD
Lisinopril—ACE—Metabolism of proteins—ACTB—esophageal cancer	2.63e-05	0.00609	CbGpPWpGaD
Lisinopril—ABCB1—Integrated Pancreatic Cancer Pathway—FKBP1A—esophageal cancer	2.46e-05	0.00569	CbGpPWpGaD
Lisinopril—ACE—Metabolism of proteins—HSPA5—esophageal cancer	2.38e-05	0.00551	CbGpPWpGaD
Lisinopril—ACE—Metabolism of proteins—CALR—esophageal cancer	2.3e-05	0.00533	CbGpPWpGaD
Lisinopril—ACE—Metabolism of proteins—GHRL—esophageal cancer	2.26e-05	0.00524	CbGpPWpGaD
Lisinopril—ABCB1—HIF-1-alpha transcription factor network—HMOX1—esophageal cancer	2.26e-05	0.00523	CbGpPWpGaD
Lisinopril—ACE—Metabolism of proteins—FBXW7—esophageal cancer	2.23e-05	0.00516	CbGpPWpGaD
Lisinopril—ABCB1—HIF-1-alpha transcription factor network—SMAD4—esophageal cancer	2.17e-05	0.00502	CbGpPWpGaD
Lisinopril—SLC15A1—Transmembrane transport of small molecules—ABCC2—esophageal cancer	2.05e-05	0.00474	CbGpPWpGaD
Lisinopril—ABCB1—Integrated Pancreatic Cancer Pathway—BBC3—esophageal cancer	1.91e-05	0.00442	CbGpPWpGaD
Lisinopril—SLC15A1—Transmembrane transport of small molecules—GNG7—esophageal cancer	1.86e-05	0.0043	CbGpPWpGaD
Lisinopril—ABCB1—HIF-1-alpha transcription factor network—HIF1A—esophageal cancer	1.77e-05	0.0041	CbGpPWpGaD
Lisinopril—ABCB1—HIF-1-alpha transcription factor network—NOS2—esophageal cancer	1.61e-05	0.00373	CbGpPWpGaD
Lisinopril—ABCB1—HIF-1-alpha transcription factor network—CREBBP—esophageal cancer	1.45e-05	0.00335	CbGpPWpGaD
Lisinopril—ABCB1—Integrated Pancreatic Cancer Pathway—ANXA1—esophageal cancer	1.3e-05	0.003	CbGpPWpGaD
Lisinopril—ABCB1—Allograft Rejection—CASP8—esophageal cancer	1.26e-05	0.00292	CbGpPWpGaD
Lisinopril—ABCB1—Integrated Pancreatic Cancer Pathway—BUB1B—esophageal cancer	1.19e-05	0.00275	CbGpPWpGaD
Lisinopril—SLC15A1—Transmembrane transport of small molecules—HMOX1—esophageal cancer	1.13e-05	0.00262	CbGpPWpGaD
Lisinopril—ABCB1—Integrated Pancreatic Cancer Pathway—CHEK2—esophageal cancer	1.13e-05	0.00261	CbGpPWpGaD
Lisinopril—ABCB1—Transmembrane transport of small molecules—SLC10A2—esophageal cancer	1.12e-05	0.0026	CbGpPWpGaD
Lisinopril—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—MYC—esophageal cancer	1.09e-05	0.00252	CbGpPWpGaD
Lisinopril—SLC15A1—Transmembrane transport of small molecules—ABCB1—esophageal cancer	1.09e-05	0.00252	CbGpPWpGaD
Lisinopril—ABCB1—Transmembrane transport of small molecules—ATP1B2—esophageal cancer	1.05e-05	0.00244	CbGpPWpGaD
Lisinopril—ABCB1—Transmembrane transport of small molecules—SLC39A6—esophageal cancer	9.99e-06	0.00231	CbGpPWpGaD
Lisinopril—ABCB1—HIF-1-alpha transcription factor network—EP300—esophageal cancer	9.86e-06	0.00228	CbGpPWpGaD
Lisinopril—ABCB1—Integrated Pancreatic Cancer Pathway—ABL1—esophageal cancer	9.56e-06	0.00221	CbGpPWpGaD
Lisinopril—ABCB1—Transmembrane transport of small molecules—AQP3—esophageal cancer	9.53e-06	0.00221	CbGpPWpGaD
Lisinopril—ABCB1—Integrated Pancreatic Cancer Pathway—SMAD4—esophageal cancer	9.26e-06	0.00214	CbGpPWpGaD
Lisinopril—ABCB1—Transmembrane transport of small molecules—SLC30A7—esophageal cancer	9.14e-06	0.00212	CbGpPWpGaD
Lisinopril—ABCB1—Transmembrane transport of small molecules—ATP4A—esophageal cancer	9.14e-06	0.00212	CbGpPWpGaD
Lisinopril—ABCB1—Integrated Pancreatic Cancer Pathway—BAX—esophageal cancer	8.76e-06	0.00203	CbGpPWpGaD
Lisinopril—SLC15A1—Transmembrane transport of small molecules—CREBBP—esophageal cancer	7.27e-06	0.00168	CbGpPWpGaD
Lisinopril—ABCB1—Transmembrane transport of small molecules—ABCC2—esophageal cancer	6.93e-06	0.0016	CbGpPWpGaD
Lisinopril—ABCB1—Transmembrane transport of small molecules—GNG7—esophageal cancer	6.28e-06	0.00146	CbGpPWpGaD
Lisinopril—ABCB1—Integrated Pancreatic Cancer Pathway—CASP8—esophageal cancer	6.21e-06	0.00144	CbGpPWpGaD
Lisinopril—ABCB1—Integrated Pancreatic Cancer Pathway—CREBBP—esophageal cancer	6.19e-06	0.00143	CbGpPWpGaD
Lisinopril—ABCB1—Metabolism—BLVRB—esophageal cancer	6.18e-06	0.00143	CbGpPWpGaD
Lisinopril—ABCB1—Metabolism—SLC52A3—esophageal cancer	6.18e-06	0.00143	CbGpPWpGaD
Lisinopril—ABCB1—Integrated Pancreatic Cancer Pathway—BCL2—esophageal cancer	5.33e-06	0.00123	CbGpPWpGaD
Lisinopril—ABCB1—Metabolism—CA1—esophageal cancer	5.25e-06	0.00122	CbGpPWpGaD
Lisinopril—ABCB1—Metabolism—SLC10A2—esophageal cancer	5.25e-06	0.00122	CbGpPWpGaD
Lisinopril—ABCB1—Integrated Pancreatic Cancer Pathway—ERBB2—esophageal cancer	5.18e-06	0.0012	CbGpPWpGaD
Lisinopril—ABCB1—Integrated Pancreatic Cancer Pathway—PTGS2—esophageal cancer	5.07e-06	0.00117	CbGpPWpGaD
Lisinopril—ABCB1—Metabolism—CA2—esophageal cancer	4.8e-06	0.00111	CbGpPWpGaD
Lisinopril—ABCB1—Integrated Pancreatic Cancer Pathway—CCND1—esophageal cancer	4.58e-06	0.00106	CbGpPWpGaD
Lisinopril—ABCB1—Metabolism—PLCE1—esophageal cancer	4.46e-06	0.00103	CbGpPWpGaD
Lisinopril—ABCB1—Metabolism—ADH7—esophageal cancer	4.46e-06	0.00103	CbGpPWpGaD
Lisinopril—ABCB1—Integrated Pancreatic Cancer Pathway—CDKN1A—esophageal cancer	4.43e-06	0.00103	CbGpPWpGaD
Lisinopril—ABCB1—Integrated Pancreatic Cancer Pathway—EP300—esophageal cancer	4.21e-06	0.000976	CbGpPWpGaD
Lisinopril—ABCB1—Metabolism—ADH1B—esophageal cancer	3.91e-06	0.000907	CbGpPWpGaD
Lisinopril—ABCB1—Transmembrane transport of small molecules—HMOX1—esophageal cancer	3.83e-06	0.000887	CbGpPWpGaD
Lisinopril—ABCB1—Metabolism—TYMP—esophageal cancer	3.74e-06	0.000866	CbGpPWpGaD
Lisinopril—ABCB1—Integrated Pancreatic Cancer Pathway—MYC—esophageal cancer	3.67e-06	0.00085	CbGpPWpGaD
Lisinopril—ABCB1—Metabolism—CYP26A1—esophageal cancer	3.64e-06	0.000843	CbGpPWpGaD
Lisinopril—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—esophageal cancer	3.59e-06	0.000832	CbGpPWpGaD
Lisinopril—ABCB1—Metabolism—ALOX15—esophageal cancer	3.55e-06	0.000821	CbGpPWpGaD
Lisinopril—ABCB1—Metabolism—GSTO1—esophageal cancer	3.38e-06	0.000784	CbGpPWpGaD
Lisinopril—ABCB1—Metabolism—TPI1—esophageal cancer	3.38e-06	0.000784	CbGpPWpGaD
Lisinopril—ABCB1—Metabolism—ALDOB—esophageal cancer	3.24e-06	0.000751	CbGpPWpGaD
Lisinopril—ABCB1—Metabolism—GAPDH—esophageal cancer	3.12e-06	0.000723	CbGpPWpGaD
Lisinopril—ABCB1—Integrated Pancreatic Cancer Pathway—PIK3CA—esophageal cancer	3.12e-06	0.000722	CbGpPWpGaD
Lisinopril—ABCB1—Metabolism—CRABP1—esophageal cancer	3.09e-06	0.000717	CbGpPWpGaD
Lisinopril—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—esophageal cancer	3.02e-06	0.000698	CbGpPWpGaD
Lisinopril—ABCB1—Metabolism—GNG7—esophageal cancer	2.94e-06	0.000682	CbGpPWpGaD
Lisinopril—ABCB1—Metabolism—ALDH2—esophageal cancer	2.76e-06	0.000639	CbGpPWpGaD
Lisinopril—ABCB1—Metabolism—GSTT1—esophageal cancer	2.62e-06	0.000608	CbGpPWpGaD
Lisinopril—ABCB1—Metabolism—CYP2A6—esophageal cancer	2.59e-06	0.000601	CbGpPWpGaD
Lisinopril—ABCB1—Metabolism—ENO1—esophageal cancer	2.46e-06	0.000569	CbGpPWpGaD
Lisinopril—ABCB1—Metabolism—PTGS1—esophageal cancer	2.46e-06	0.000569	CbGpPWpGaD
Lisinopril—ABCB1—Transmembrane transport of small molecules—CREBBP—esophageal cancer	2.46e-06	0.000569	CbGpPWpGaD
Lisinopril—ABCB1—Metabolism—PSME1—esophageal cancer	2.42e-06	0.000561	CbGpPWpGaD
Lisinopril—ABCB1—Metabolism—PSME2—esophageal cancer	2.42e-06	0.000561	CbGpPWpGaD
Lisinopril—ABCB1—Metabolism—CYP1B1—esophageal cancer	2.09e-06	0.000484	CbGpPWpGaD
Lisinopril—ABCB1—Metabolism—CYP19A1—esophageal cancer	1.97e-06	0.000455	CbGpPWpGaD
Lisinopril—ABCB1—Metabolism—HMOX1—esophageal cancer	1.79e-06	0.000415	CbGpPWpGaD
Lisinopril—ABCB1—Metabolism—CREBBP—esophageal cancer	1.15e-06	0.000266	CbGpPWpGaD
Lisinopril—ABCB1—Metabolism—NOS3—esophageal cancer	1.03e-06	0.000239	CbGpPWpGaD
Lisinopril—ABCB1—Metabolism—PTGS2—esophageal cancer	9.42e-07	0.000218	CbGpPWpGaD
Lisinopril—ABCB1—Metabolism—EP300—esophageal cancer	7.84e-07	0.000181	CbGpPWpGaD
Lisinopril—ABCB1—Metabolism—PIK3CA—esophageal cancer	5.8e-07	0.000134	CbGpPWpGaD
